Janssen's aticaprant MDD trial terminated early; new J&J-linked prostate trial registered
Janssen's long-term aticaprant safety study for depression was stopped early by sponsor decision, while Fred Hutchinson Cancer Center registered a neoadjuvant pasritamig trial with J&J as collaborator.
Two items this week span a terminated depression study and a newly registered prostate cancer trial.
- Janssen's open-label study of aticaprant as adjunctive therapy for major depressive disorder, "VENTURA-LT" (NCT05518149), was early terminated as per sponsor's decision, communicated to sites on 06Mar20251. The phase 3 trial had enrollment of 871 participants1, testing Aticaprant 10 milligrams once daily, orally in addition to the current antidepressant SSRI/SNRI therapy on Day 1 up to 52 weeks1.
- Fred Hutchinson Cancer Center registered a phase 1 neoadjuvant trial of pasritamig in localized prostate cancer (NCT07860255), listing Johnson & Johnson as a collaborator. The study is not yet recruiting2, with an enrollment of 18 participants (estimated)2, and will give pasritamig IV on days 1, 8, 15, and 572 before patients undergo standard of care radical prostatectomy2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.